Farxiga Tablet, Film Coated
Product Images NDC 0310-6205

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 0310-6205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
FDA Label Image

Figure 6a (Figure 6a)

Figure 6a (Figure 6a)
This is a comparison between the effectiveness of the drug FARXIGA versus a placebo treatment in reducing an event in patients. The graph shows the percentage of patients with a positive outcome over the course of 24 months from randomization. The drug FARXIGA was found to be more effective at reducing the occurrence of the event compared to the placebo treatment as evidenced by the HR (hazard ratio) of 0.74 and a p-value that was not made available.*
FDA Label Image

Figure 6b (Figure 6b)

Figure 6b (Figure 6b)
The text seems to be a statistical comparison between two groups (FARXIGA and Placebo) in a medical study, represented in a graph showing the percentage of patients with an event over months from randomization. FARXIGA group had a HR (hazard ratio) of 0.82 and a P-value of 0.0294 compared to Placebo. The graph also shows the number of patients at risk over the duration of the study.*
FDA Label Image

Figure 6c (Figure 6c)

Figure 6c (Figure 6c)
This appears to be a statistical comparison between a medication called FARXIGA and a placebo. The data shows the percentage of patients with an event, and includes a graph displaying the results over a 24-month period. The HR (hazard ratio) is also provided, along with a P-value of less than 0.0001. Overall, it seems that FARXIGA performed better than the placebo in this study.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
FDA Label Image

Farxiga 10 mg Bottle Label (Farxiga 10mg 30s)

Farxiga 10 mg Bottle Label (Farxiga 10mg 30s)
This is a description of Farxiga tablets. The package contains 130 tablets with NDC code 0310-6210-30. It is a medication that contains dapagliflozin and should be dispensed with a medication guide. The GTIN code for this package is 00303106210305. The manufacturer is AstraZeneca Pharmaceuticals and is based in Sodertile, Sweden. It is only available with a prescription (Rx only).*
FDA Label Image

Farxiga 5 mg Bottle Label (Farxiga 5mg 30s)

Farxiga 5 mg Bottle Label (Farxiga 5mg 30s)
This is a description of medication called Farxiga in tablet form with a strength of 5mg. The medication comes in a package with 30 tablets and can be identified using the GTIN as 00303106205301. There is an instruction to dispense the medication with a medication guide, however, no information regarding the medication guide is provided. At the bottom, there is an indication that the medication is patented by AstraZeneca.*
FDA Label Image

Figure 1 (Farxiga Fig1)

Figure 1 (Farxiga Fig1)
This appears to be a graph showing the relationship between dapagliflozin dose (in mg) and 24-hour urinary glucose (in g) for healthy subjects and subjects with T20M. Fitted lines are shown for both groups. No other information is available.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
This data presents the results of a comparison between FARXIGA and placebo in 244 patients. The patients who took FARXIGA had a significantly lower rate of the event being measured compared to those who took the placebo. The number of patients at risk is given for both groups at each point in time over a 32 month period.*
FDA Label Image

Farxiga Figure 2 (Image 01)

Farxiga Figure 2 (Image 01)
FDA Label Image

Farxiga Figure 3 (Image 02)

Farxiga Figure 3 (Image 02)
This is a graph showing the adjusted mean change from baseline HbA1c levels over a study period of 24 weeks. It compares the effectiveness of a placebo plus metformin to Farxiga 10 mg plus metformin in randomized subjects completing a short-term period without rescue. The data is based on longitudinal repeated measures and ANCOVA models. The graph and data are useful in determining the efficacy of Farxiga 10 mg plus metformin in managing HbA1c levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.